Philogen stock

PHIL · Borsa Italiana · EUR

Compare Philogen
€20.95Change from previous close: +2.20%Absolute change: +€0.45

Close · November 20, 2026

Price history

−10.85% over the period

1 year: from €23.50 (November 20, 2025) to €20.95 (November 20, 2026), −10.85%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€20.95
October 30, 2026€20.70
September 30, 2026€22.50
August 31, 2026€23.05
July 31, 2026€23.80
June 30, 2026€23.20
May 29, 2026€23.25
April 30, 2026€21.65
March 31, 2026€22.70
February 27, 2026€21.00
January 30, 2026€21.00
December 30, 2025€23.30
November 28, 2025€24.10
November 20, 2025€23.50

At a glance

  • The company

    Biotechnology company developing drugs for oncology and chronic inflammatory diseases

  • Latest results

    Quarter to June 30, 2026 · EPS -€0.49

TickerLandia's take on Philogen

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€19.56
52-wk high€26.00

−19.42% from the 52-week high

Analysts · 3 analysts

Average target€28.33+35.24% vs. price

Buy 2 · Hold 1 · Sell 0

TickerLandia Fingerprint: Philogen

Compared with similar companies: very low price and very high profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Philogen is cheaper than similar companies

Philogen's P/E (trailing 12 months): 3.67, −75% against the median of a group of 7 similar companies (14.7).

Compared with 7 similar companies

Philogen's metrics compared with similar companies
MetricPhilogenPosition in the groupBand
P/E (trailing 12 months)3.67Low
Operating margin79.1%High
ROE98.4%High
Debt/equity0.03Middle
Price/book2.49Low

Grey band: the middle half of the group; tick: the median; dot: Philogen. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€4.07M

Latest quarter · Q2 2026

Net income

-€19.59M

Latest quarter · Q2 2026

Quarterly net margin

-482.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€824.35M
P/E
3.7
EPS
€5.58
Volume
27.13K
Daily trading
€285.89K
Dividend yield
3.34%
Last ex-dividend on May 18, 2026

How Philogen is changing

All results
  • Revenue grew 119.0% a year on average over the last 5 years

  • Operating margin rose from −0.5% to 80.4%

  • Profits turn into cash: free cash flow equal to 109% of net income

Returns

Philogen returns with dividends

€1,000 invested in Philogen 5 years ago, on November 22, 2021, would be worth €1,425 today: +42.52% in total, +7.35% per year. This is the price return only: dividends are excluded.

PeriodPhilogenFTSE MIB€1,000 becomes
1 month−3.23%−0.75%€968
6 months−5.63%−0.97%€944
Year to date−10.09%+8.36%€899
1 year−8.03%+13.48%€920
3 years+16.39%+64.86%€1,164
5 years+42.52%+77.86%€1,425

Over the last 6 months it has done better than 15% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment

The chart in detail

Philogen: technical analysis

Philogen is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 23.5% below its all-time closing high (€27.40, June 12, 2025).

Trend
Downward
RSI (14 sessions)
47
Between 30 and 70
vs 200-session average
−6.59%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 17, 2026

  • Trading on November 20, 2026 was 2.5 times the 20-session average.

    since November 18, 2026

Support and resistance

Price areas where Philogen has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€22.68+8.26%5 touches, last on September 15, 2026
  2. Resistance€22.16+5.80%7 touches, last on October 27, 2026
  3. Resistance€21.54+2.82%6 touches, last on November 10, 2026
  4. Last price€20.95
  5. Support€20.87−0.40%3 touches, last on October 20, 2026
  6. Support€20.45−2.39%3 touches, last on November 3, 2026

Volatility and risk

Over the last year it has moved little with the FTSE MIB.

Beta (1 year) vs FTSE MIB
0.23
Volatility (60 sessions, annualised)
23.6%
Largest fall in the last year
−20.54%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Philogen: seasonality

Average monthly price change over 6 years

−4.5%Jan+2.9%Feb+2.0%Mar+0.6%Apr+5.6%May−2.0%Jun+2.6%Jul+1.5%Aug−3.7%Sep+1.2%Oct+0.3%Nov+0.2%Dec

Over the last 6 years, the strongest month for Philogen has been May: +5.55% on average, positive in 5 years out of 6. The weakest has been January: −4.51% on average, positive in 1 years out of 5. November, the current month, has been positive in 2 years out of 5 (+0.29% on average).

Show chart data
MonthAverageMedianPositive years
January−4.51%−7.84%1 of 5
February+2.89%+1.68%3 of 5
March+2.03%+3.23%3 of 5
April+0.61%+0.50%3 of 6
May+5.55%+3.75%5 of 6
June−2.00%−2.94%1 of 6
July+2.60%+3.33%5 of 6
August+1.54%+1.49%4 of 6
September−3.72%−4.27%2 of 6
October+1.23%+2.61%4 of 6
November+0.29%−1.85%2 of 5
December+0.18%+0.82%3 of 5

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Philogen and its competitors

Philogen reported revenue of 319.7 million euros in the fiscal year ended 31 December 2025, and its work centres on drugs for cancer and chronic inflammatory conditions. Nidlegy is in Phase III testing for advanced melanoma and Fibromun in Phase III for soft-tissue sarcoma, while Darleukin, Dekavil and Dodekin are in earlier-stage trials for lung cancer, chronic inflammatory disorders and various solid tumors. A second line of small molecules, including OncoFAP, OncoACP3 and OncoCAIX, targets solid tumors, prostate cancer and renal cell carcinoma. The company operates in Italy, Switzerland, the United States and the European Union.

Headquarters
Sovicille, Italy
Employees
230
Founded
1996
Chief executive
Dario Neri
Philogen and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
PhilogenPHIL$905.96M79.1%3.67−5.63%
InventivaIVA$890.8M-5,980.9%—−33.75%
Pharming GroupPHARM$841.25M12.8%36.1−2.57%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%
Pharma MarPHM$1.1B21.3%14.7−41.56%
GubraGUBRA$730.02M-73.1%—−22.24%

Same industry or related industries, similar size. Compare Philogen with its competitors · Full profile